How many classes are in the Biopharmaceutics Classification System (BCS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Biopharmaceutics Classification System (BCS) Classes

C) Four classes is the correct answer.

BCS Framework

The Biopharmaceutics Classification System (BCS) categorizes drugs into four distinct classes based on two fundamental biopharmaceutical properties: aqueous solubility and intestinal membrane permeability 1, 2.

The Four BCS Classes

The classification scheme divides drugs as follows 1, 3:

  • Class I: High solubility, high permeability
  • Class II: Low solubility, high permeability
  • Class III: High solubility, low permeability
  • Class IV: Low solubility, low permeability

Clinical Significance

The BCS captures the two most significant factors influencing oral drug absorption and has become a cornerstone for drug discovery, product development, and regulatory sciences since its introduction in 1995 1, 2.

Distribution Among Essential Medicines

Analysis of the World Health Organization's Model List of Essential Medicines revealed the following distribution among classified drugs 3:

  • 84% belong to Class I (highly soluble, highly permeable)
  • 17% belong to Class II (poorly soluble, highly permeable)
  • 39% belong to Class III (highly soluble, poorly permeable)
  • 10% belong to Class IV (poorly soluble, poorly permeable)

Regulatory Impact

The majority of approved immediate-release oral drug products can have their clinical performance assured with in vitro dissolution testing rather than empirical in vivo human studies, particularly for Class I drugs 1. Drug regulatory agencies worldwide have effectively implemented the BCS in setting bioavailability/bioequivalence standards for immediate-release oral drug product approval 1.

Important Refinements

While the original BCS defines four classes, sub-classifications have been proposed for Classes II and IV to account for acid (a), base (b), and neutral (c) compounds, as the pKa significantly impacts dissolution behavior in the variable pH environment of the gastrointestinal tract 2. However, the fundamental system remains four classes 1, 2, 3.

References

Research

The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2014

Research

Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2004

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.